Actavis PLC (ACT) News Nov 18, 2014, 7:58 p.m. Ma
Post# of 250665
Posted On: 11/18/2014 9:32:20 PM
Actavis PLC (ACT) News Nov 18, 2014, 7:58 p.m.
MarketWatch News on ACT
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Today - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Today - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Today - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Small-cap buckling and trap doors could make for a brutal earnings season 6:07 a.m. Oct. 8, 2014 - Shawn Langlois
Valeant to boost Allergan bid by $15 a share: report 5:48 p.m. Oct. 7, 2014 - Russ Britt
Loading more headlines...
Advertisement
Other News on ACT
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous 8:10 p.m. Today - TheStreet.com
Goldman Hits Mother Lode on Deals 7:27 p.m. Today - The Wall Street Journal Interactive Edition
Ackman Drops Push for Allergan Meeting 6:19 p.m. Today - The Wall Street Journal Interactive Edition
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog 5:05 p.m. Today - Zacks.com
Market News: Actavis Plc, SunEdison Inc, Halliburton Company 4:54 p.m. Today - TheStreet.com
Stock Market Today: Oil Slump Fuels S&P 500 to Fresh Record High 4:09 p.m. Today - TheStreet.com
Hottest Healthcare Stocks Now – ACT SGEN MNKD PBYI 3:15 p.m. Today - InvestorPlace.com
Actavis-Allergan Deal Friendly to Shareholders 2:58 p.m. Today - Barrons.com
Stock Market Today: S&P 500 Notches New High as Oil Prices Slip and Slide 2:23 p.m. Today - TheStreet.com
Zoetis 2015 Guidance Misses As Buyout Theories Abound 2:15 p.m. Today - Investors Business Daily
Stock Movers: Why 4 Big Drug Stocks Are Rising Today 1:38 p.m. Today - Investors Business Daily
Actavis Strikes $66 Billion Deal for Botox Maker Allergan - Analyst Blog 1:20 p.m. Today - Zacks.com
Pharma ETFs in Focus on Allergan Takeover Deal - ETF News And Commentary 1:00 p.m. Today - Zacks.com
Teva wins Actonel patent appeal 12:06 p.m. Today - Seeking Alpha
Actavis (ACT) Is Today's Unusual Social Activity Stock 11:14 a.m. Today - TheStreet.com
One Factor Driving Up Actavis (ACT) Stock Today 11:06 a.m. Today - TheStreet.com
AstraZeneca Bets Long Term on Cancer Drugs 10:53 a.m. Today - The Wall Street Journal Interactive Edition
Stock Market News for November 18, 2014 - Market News 10:10 a.m. Today - Zacks.com
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit? 8:32 a.m. Today - Seeking Alpha
Should Investors View the U.S. Market as a Safe Zone? 5:35 a.m. Today - InvestorPlace.com
Loading more headlines...
Press Releases on ACT
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting 8:00 a.m. Oct. 9, 2014 - BusinessWire - BZX
EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX 11:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:34 a.m. Oct. 6, 2014 - PR Newswire - PRF
Loading more headlines...
MarketWatch News on ACT
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Today - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Today - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Today - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Small-cap buckling and trap doors could make for a brutal earnings season 6:07 a.m. Oct. 8, 2014 - Shawn Langlois
Valeant to boost Allergan bid by $15 a share: report 5:48 p.m. Oct. 7, 2014 - Russ Britt
Loading more headlines...
Advertisement
Other News on ACT
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous 8:10 p.m. Today - TheStreet.com
Goldman Hits Mother Lode on Deals 7:27 p.m. Today - The Wall Street Journal Interactive Edition
Ackman Drops Push for Allergan Meeting 6:19 p.m. Today - The Wall Street Journal Interactive Edition
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog 5:05 p.m. Today - Zacks.com
Market News: Actavis Plc, SunEdison Inc, Halliburton Company 4:54 p.m. Today - TheStreet.com
Stock Market Today: Oil Slump Fuels S&P 500 to Fresh Record High 4:09 p.m. Today - TheStreet.com
Hottest Healthcare Stocks Now – ACT SGEN MNKD PBYI 3:15 p.m. Today - InvestorPlace.com
Actavis-Allergan Deal Friendly to Shareholders 2:58 p.m. Today - Barrons.com
Stock Market Today: S&P 500 Notches New High as Oil Prices Slip and Slide 2:23 p.m. Today - TheStreet.com
Zoetis 2015 Guidance Misses As Buyout Theories Abound 2:15 p.m. Today - Investors Business Daily
Stock Movers: Why 4 Big Drug Stocks Are Rising Today 1:38 p.m. Today - Investors Business Daily
Actavis Strikes $66 Billion Deal for Botox Maker Allergan - Analyst Blog 1:20 p.m. Today - Zacks.com
Pharma ETFs in Focus on Allergan Takeover Deal - ETF News And Commentary 1:00 p.m. Today - Zacks.com
Teva wins Actonel patent appeal 12:06 p.m. Today - Seeking Alpha
Actavis (ACT) Is Today's Unusual Social Activity Stock 11:14 a.m. Today - TheStreet.com
One Factor Driving Up Actavis (ACT) Stock Today 11:06 a.m. Today - TheStreet.com
AstraZeneca Bets Long Term on Cancer Drugs 10:53 a.m. Today - The Wall Street Journal Interactive Edition
Stock Market News for November 18, 2014 - Market News 10:10 a.m. Today - Zacks.com
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit? 8:32 a.m. Today - Seeking Alpha
Should Investors View the U.S. Market as a Safe Zone? 5:35 a.m. Today - InvestorPlace.com
Loading more headlines...
Press Releases on ACT
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting 8:00 a.m. Oct. 9, 2014 - BusinessWire - BZX
EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX 11:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:34 a.m. Oct. 6, 2014 - PR Newswire - PRF
Loading more headlines...
(0)
(0)